LipoCol Forte capsules reduce the risk of liver cancer:A propensity score-matched,nationwide,population-based cohort study  

作　　者：Hsiang-Chun Lai Hung-Jen Lin Ying-Hsiu Shih Jen-Wei Chou Kuan-Wen Lin Long-Bin Jeng Sheng-Teng Huang 

机构地区：[1]Graduate Institute of Chinese Medicine,School of Chinese Medicine,College of Chinese Medicine,China Medical University,Taichung 40447,Taiwan [2]School of Post-Baccalaureate Chinese Medicine,College of Chinese Medicine,China Medical University,Taichung 40402,Taiwan [3]Management Office for Health Data,China Medical University Hospital,Taichung 40447,Taiwan [4]Department of Internal Medicine,China Medical University Hospital,Taichung 40447,Taiwan [5]Department of Surgery,China Medical University Hospital,Taichung 40447,Taiwan [6]Organ Transplantation Center,China Medical University Hospital,Taichung 40447,Taiwan [7]Department of Chinese Medicine,China Medical University Hospital,Taichung 40447,Taiwan [8]Cancer Research Center for Traditional Chinese Medicine,Department of Medical Research,China Medical University Hospital,Taichung 40447,Taiwan [9]An-Nan Hospital,China Medical University,Tainan 709204,Taiwan [10]School of Chinese Medicine,China Medical University,Taichung 40447,Taiwan

出　　处：《World Journal of Gastrointestinal Oncology》2023年第5期828-842,共15页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by the Ministry of Science and Technology of Taiwan,No. NSTC111-2320-B-039-025;China Medical University Hospital,No. DMR-111-013 and No. DMR-111-195

摘　　要：BACKGROUND Liver cancer is among the top five most common cancers globally. Lipid-lowering drugs such as statins can lower the risk of liver cancer, but may also cause liver damage. LipoCol Forte capsules(LFC), a red yeast rice product, have demonstrated significant antihypercholesterolemic effects and a good safety profile in clinical studies.AIM To evaluate whether LFC lowers the risk of liver cancer in adults in this propensity score-matched, nationwide, population-based cohort study.METHODS We used data from Taiwan’s National Health Insurance Research Database, which includes electronic medical records for up to 99.99% of Taiwan’s population. LFC users and LFC non-users were matched 1:1 by propensity scores between January 2010 and December 2017. All had followup data for at least 1 year. Statistical analyses compared demographic distributions including sex, age, comorbidities, and prescribed medications. Cox regression analyses estimated adjusted hazard ratios(aHRs) after adjusting for potential confounders.RESULTS We enrolled 33231 LFC users and 33231 non-LFC users(controls). No significant differences between the study cohorts were identified regarding comorbidities and medications [standardized mean difference(SMD) < 0.05]. At follow-up, the overall incidence of liver cancer was significantly lower in the LFC cohort compared with controls [aHR 0.91;95% confidence interval(CI): 0.86-0.95;P < 0.001]. The risk of liver cancer was significantly reduced in both females(aHR 0.87;95%CI: 0.8-0.94;P < 0.001) and males(aHR 0.93;95%CI: 0.87-0.98;P < 0.01) in the LFC cohort compared with their counterparts in the non-LFC cohort. The antitumor protective effects applied to patients with comorbidities(including hypertension, ischemic stroke, diabetes mellitus, hyperlipidemia, hepatitis B infection and hepatitis C infection). Those using LFC for more than 84 drug days had a 0.64-fold lower risk of liver cancer compared with controls(P < 0.001). Compared with controls, the risk of developing liver cancer in the LFC c

关 键 词：LipoCol Forte capsules HYPERLIPIDEMIA Liver cancer Hepatocellular carcinoma Retrospective cohort study Taiwan National Health Insurance Research Database 

分 类 号：R730.1[医药卫生—肿瘤]